搜索医生

Mabel Ryder, M.D.

  1. Endocrinologist
预约门诊

出版物

  1. Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, Berkenstock MK, Bermas B, Braaten T, Budde LE, Chokshi S, Crees ZD, Davies M, Deng C, Gesthalter Y, Jain M, Jain P, Jallouk A, Kaffenberger BH, Khalil M, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Prosek J, Reddy S, Reid P, Ryan J, Ryder M, Salman H, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Zucker S, Lyons M, Awotiwon A, Hang L. NCCN Guidelines(R) Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Netw. 2024 Nov; 22 (9):582-592
    View PubMed
  2. Lee KK, Morris JC 3rd, Kumar A, Chintakuntlawar AV, Peskey C, Hilger CR, Bible KC, Ryder M. Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers. Head Neck. 2024 Oct 27 [Epub ahead of print]
    View PubMed
  3. Frota Lima LM, Bogsrud TV, Gharib H, Ryder M, Johnson G, Durski J. Risk of malignancy in thyroid nodules with increased 11C-Choline uptake detected incidentally on PET/CT: A diagnostic accuracy study. Medicine (Baltimore). 2024 Sep 6; 103 (36):e39602
    View PubMed
  4. Konda B, Sherman EJ, Massarelli E, Nieva J, Muzaffar J, Morris Iii JC, Ryder M, Ho AL, Agulnik M, Wei L, Handley D, Moses C, Jacob R, Wright J, Streicher H, Carson W, Shah MH. Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer. J Clin Endocrinol Metab. 2024 Aug 12 [Epub ahead of print]
    View PubMed
  5. Abrahao R, Brunson A, Ruddy KJ, Li Q, Li J, Ryder MM, Chubak J, Nichols HB, Sauder CAM, Gray MF, Hahn EE, Wun T, Keegan THM. Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study. Br J Cancer. 2024 Apr; 130 (7):1166-1175 Epub 2024 Feb 08
    View PubMed
  6. Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, McIver B, McMullen CP, Newbold K, Rocke DJ, Russell MD, Ryder M, Sadow PM, Sherman E, Shindo M, Shonka DC Jr, Singer MC, Stack BC Jr, Wirth LJ, Wong RJ, Randolph GW. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update. JAMA Otolaryngol Head Neck Surg. 2024 Mar 1; 150 (3):265-272
    View PubMed
  7. Singh Ospina N, Patel Chavez C, Godinez Leiva E, Bagautdinova D, Hidalgo J, Hartasanchez S, Algarin Perneth S, Barb D, Danan D, Dziegielewski P, Hughley B, Srihari A, Subbarayan S, Castro MR, Dean D, Morris J, Ryder M, Stan MN, Hargraves I, Bylund CL, Treise D, Montori VM, Brito JP. Clinician feedback using a shared decision-making tool for the evaluation of patients with thyroid nodules-an observational study. Endocrine. 2024 Feb; 83 (2):449-458 Epub 2023 Sept 11
    View PubMed
  8. Toro-Tobon D, Morris JC, Hilger C, Peskey C, Durski JM, Ryder M. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers. Thyroid. 2024 Jan; 34 (1):70-81 Epub 2023 Dec 12
    View PubMed
  9. Boucai L, Saqcena M, Kuo F, Grewal RK, Socci N, Knauf JA, Krishnamoorthy GP, Ryder M, Ho AL, Ghossein RA, Morris LGT, Seshan V, Fagin JA. Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy. Clin Cancer Res. 2023 Apr 14; 29 (8):1620-1630
    View PubMed
  10. Patel Chavez CP, Godinez Leiva E, Bagautdinova D, Hidalgo J, Hartasanchez S, Barb D, Danan D, Dziegielewski P, Edwards C, Hughley B, Srihari A, Subbarayan S, Castro MR, Dean D, Morris J, Ryder M, Stan MN, Hargraves I, Shepel K, Brito JP, Bylund CL, Treise D, Montori V, Singh Ospina N. Patient feedback receiving care using a shared decision making tool for thyroid nodule evaluation-an observational study. Endocrine. 2023 Apr; 80 (1):124-133 Epub 2022 Dec 19
    View PubMed
  11. Kotwal A, Gustafson MP, Bornschlegl S, Dietz AB, Delivanis D, Ryder M. Circulating immunophenotypes are potentially prognostic in follicular cell-derived thyroid cancer. Front Immunol. 2023; 14:1325343. Epub 2024 Jan 03.
    View PubMed
  12. Kohlenberg J, Gu J, Parvinian A, Webb J, Kawkgi OE, Larson NB, Ryder M, Fatemi M, Alizad A. Added value of mass characteristic frequency to 2-D shear wave elastography for differentiation of benign and malignant thyroid nodules. Ultrasound Med Biol. 2022 Aug; 48 (8):1663-1671 Epub 2022 June 04
    View PubMed
  13. Shonka DC Jr, Ho A, Chintakuntlawar AV, Geiger JL, Park JC, Seetharamu N, Jasim S, Abdelhamid Ahmed AH, Bible KC, Brose MS, Cabanillas ME, Dabekaussen K, Davies L, Dias-Santagata D, Fagin JA, Faquin WC, Ghossein RA, Gopal RK, Miyauchi A, Nikiforov YE, Ringel MD, Robinson B, Ryder MM, Sherman EJ, Sadow PM, Shin JJ, Stack BC Jr, Tuttle RM, Wirth LJ, Zafereo ME Jr, Randolph GW. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022 Jun; 44 (6):1277-1300 Epub 2022 Mar 11
    View PubMed
  14. Hassan Nelson L, Fuentes-Bayne H, Yin J, Asmus E, Ryder M, Morris JC, Hilger CR, Bible KC, Chintakuntlawar AV, Rao SN. Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas. J Endocr Soc. 2022 May 01; 6(5):bvac044. Epub 2022 Mar 22.
    View PubMed
  15. Kotwal A, Rouleau SG, Dasari S, Kottschade L, Ryder M, Kudva YC, Markovic S, Erickson D. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort. J Investig Med. 2022 Apr; 70 (4):939-946 Epub 2021 Dec 29
    View PubMed
  16. Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Apr; 20 (4):387-405
    View PubMed
  17. Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. Management of immunotherapy-related toxicities, version 1.2022. Journal of the National Comprehensive Cancer Network. 2022 Apr; 20 (4):387-405
  18. Gao RW, Foote RL, Garces YI, Ma DJ, Neben-Wittich M, Routman DM, Patel SH, Ko SJ, McGee LA, Bible KC, Chintakuntlawar AV, Ryder M, Morris JC, Van Abel KM, Rivera M, Abraha F, Lester SC. Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive Chemoradiotherapy. Pract Radiat Oncol. 2022 Mar-Apr; 12 (2):113-119 Epub 2021 Oct 26
    View PubMed
  19. Lechner MG, Ryder M. Insights into immune checkpoint inhibitor-induced thyroiditis. Nat Rev Endocrinol 2021 Nov; 17 (11):643-644
    View PubMed
  20. Kotwal A, Ryder M. Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers. Curr Opin Endocrinol Diabetes Obes. 2021 Oct 1; 28 (5):517-524
    View PubMed
  21. Ryder M, Wentworth M, Algeciras-Schimnich A, Morris JC, Garrity J, Sanders J, Young S, Sanders P, Furmaniak J, Rees Smith B. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy. Thyroid. 2021 Oct; 31 (10):1597-1602 Epub 2021 July 08
    View PubMed
  22. Yin LX, Puccinelli CL, Van Abel K, Kasperbauer JL, Price DL, Janus JR, Ryder M, Moore EJ. Prognostic Factors in Patients with Differentiated Thyroid Cancers Metastatic to the Cervical Spine. Laryngoscope. 2021 May; 131 (5):E1741-E1747 Epub 2020 Oct 23
    View PubMed
  23. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021 Apr 1; 50 (4):469-493
    View PubMed
  24. Durski JM, Hruska CB, Bogsrud TV, Ryder M, Johnson GB. 123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer. Clin Nucl Med. 2021 Mar 1; 46 (3):e151-e153
    View PubMed
  25. Bornschlegl S, Gustafson MP, Delivanis DA, Ryder M, Liu MC, Vasmatzis G, Hallemeier CL, Park SS, Roberts LR, Parney IF, Jelinek DF, Dietz AB. Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. Clin Transl Immunology. 2021; 10(4):e1267. Epub 2021 Apr 29.
    View PubMed
  26. Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB, Gandhi M, Ryder M. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. Thyroid. 2020 Oct; 30 (10):1440-1450 Epub 2020 May 21
    View PubMed
  27. Venable ER, Kerr SE, Lopes MBS, Jones KA, Bellizzi AM, Mounajjed T, Raghunathan A, Hamidi O, Halfdanarson TR, Ryder M, Graham RP. Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases. Diagn Pathol. 2020 Jul 4; 15 (1):81 Epub 2020 July 04
    View PubMed
  28. Iniguez-Ariza NM, Jasim S, Ryder MM, Chintakuntlawar AV, Morris JC, Hilger CR, Menefee ME, Smallridge RC, Karlin NJ, Alcaino C, Bible KC. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. J Clin Endocrinol Metab. 2020 Jul 1; 105 (7)
    View PubMed
  29. Miller KC, Chintakuntlawar AV, Hilger C, Bancos I, Morris JC, Ryder M, Smith CY, Jenkins SM, Bible KC. Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. J Endocr Soc. 2020 Jul 1; 4 (7):bvaa069 Epub 2020 June 09
    View PubMed
  30. Bedrose S, Miller KC, Altameemi L, Ali MS, Nassar S, Garg N, Daher M, Eaton KD, Yorio JT, Daniel DB, Campbell M, Bible KC, Ryder M, Chintakuntlawar AV, Habra MA. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J Immunother Cancer. 2020 Jul; 8 (2)
    View PubMed
  31. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar; 18 (3):230-241
    View PubMed
  32. Kotwal A, Kottschade L, Ryder M. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid. 2020 Feb; 30 (2):177-184 Epub 2020 Jan 09
    View PubMed
  33. Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev. 2019 Dec 1; 40 (6):1573-1604
    View PubMed
  34. Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces Y, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ, Morris JC 3rd, Neben-Wittich M, Price DL, Price KA, Ryder M, Van Abel KM, Hilger C, Samb E, Bible KC. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid. 2019 Nov; 29 (11):1615-1622
    View PubMed
  35. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019 Mar 1; 17 (3):255-289
    View PubMed
  36. Strajina V, Dy BM, McKenzie TJ, Al-Hilli Z, Lee RA, Ryder M, Farley DR, Thompson GB, Lyden ML. Treatment of lateral neck papillary thyroid carcinoma recurrence after selective lateral neck dissection. Surgery. 2019 Jan; 165 (1):31-36 Epub 2018 Oct 09
    View PubMed
  37. Strajina V, Dy BM, McKenzie TJ, Al-Hilli Z, Ryder M, Farley DR, Thompson GB, Lyden ML. Comprehensive Lateral Neck Dissection in Papillary Thyroid Carcinoma may Reduce Lateral Neck Recurrence Rates. Ann Surg Oncol. 2019 Jan; 26 (1):86-92 Epub 2018 Nov 08
    View PubMed
  38. Gregory A, Bayat M, Kumar V, Denis M, Kim BH, Webb J, Meixner DD, Ryder M, Knudsen JM, Chen S, Fatemi M, Alizad A. Differentiation of Benign and Malignant Thyroid Nodules by Using Comb-push Ultrasound Shear Elastography: A Preliminary Two-plane View Study. Acad Radiol. 2018 Nov; 25 (11):1388-1397 Epub 2018 Mar 21
    View PubMed
  39. Ryder M, Randolph G. 88(th)Annual Meeting of the American Thyroid Association October 3-7, 2018 Marriott Marquis, Washington, DC. Thyroid. 2018 Sep 7 Epub 2018 Sept 07
    View PubMed
  40. Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA. Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. J Clin Endocrinol Metab. 2018 Sep 1; 103 (9):3169-3182
    View PubMed
  41. Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Neben Wittich MA, Wittich MAN, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M, Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC, Bible KC. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2017 Dec 1; 102 (12):4506-4514
    View PubMed
  42. Jasim S, Iniguez-Ariza NM, Hilger CR, Chintakuntlawar AV, Ryder MM, Morris JC 3rd, Bible KC. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS. Endocr Pract. 2017 Aug 17;
    View PubMed
  43. Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab. 2017 Aug 01; 102(8):2770-2780.
    View PubMed
  44. Iniguez-Ariza NM, Ryder MM, Hilger CR, Bible KC. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. Thyroid. 2017 Jul; 27 (7):923-927 Epub 2017 May 31
    View PubMed
  45. French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017 Jun; 5 (6):469-481 Epub 2016 Oct 20
    View PubMed
  46. Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C, Bible KC. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J Clin Endocrinol Metab. 2017 Jun 01; 102(6):1943-1950.
    View PubMed
  47. Merten MM, Castro MR, Zhang J, Durski J, Ryder M. Examining the Role of Preoperative Positron Emission Tomography/Computerized Tomography in Combination with Ultrasonography in Discriminating Benign from Malignant Cytologically Indeterminate Thyroid Nodules. Thyroid. 2017 Jan; 27 (1):95-102 Epub 2016 Dec 05
    View PubMed
  48. Espinosa De Ycaza AE, Lowe KM, Dean DS, Castro MR, Fatourechi V, Ryder M, Morris JC, Stan MN. Risk of Malignancy in Thyroid Nodules with Non-Diagnostic Fine-Needle Aspiration: A Retrospective Cohort Study. Thyroid. 2016 Nov; 26 (11):1598-1604 Epub 2016 Oct 05
    View PubMed
  49. Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J, Mosca P, Markovic S, Midwest Melanoma Partnership. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res. 2016 Oct; 26 (5):469-80
    View PubMed
  50. Bible KC, Ryder M. Mutated BRAF and personalised medicine in differentiated thyroid cancer. Lancet Oncol 2016 Sep; 17 (9):1181-3 Epub 2016 July 23
    View PubMed
  51. Bible KC, Ryder M. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol. 2016 Jul; 13 (7):403-16 Epub 2016 Mar 01
    View PubMed
  52. Bible KC, Chintakuntlawar AV, Ryder M. Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. J Oncol Pract 2016 Jun; 12 (6):521-2
    View PubMed
  53. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014 Apr; 21: (2)371-81.
    View PubMed
  54. Gustafson MP, Lin Y, Ryder M, Dietz AB. Strategies for improving the reporting of human immunophenotypes by flow cytometry. J Immunother Cancer. 2014; 2:18 Epub 2014 June 18
    View PubMed
  55. Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr Relat Cancer. 2013 Oct; 20(5):659-67. Epub 2013 Aug 21
    View PubMed
  56. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA, Fagin JA. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One. 2013; 8(1):e54302. Epub 2013 Jan 23.
    View PubMed
  57. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011 Dec; 121(12):4700-11. Epub 2011 Nov 21
    View PubMed
  58. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene. 2011 Jul 14; 30(28):3153-62. Epub 2011 Mar 07.
    View PubMed
  59. Heidi H, Gopalakrishna NI, Carlson DL, Stambuck H, Ryder M, Ganly, I. Functional glomus vagale: a case report illustrating diagnosis and management. Skull Base. 2010; 20:491-6.
  60. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009 Jun 1; 69(11):4885-93.
    View PubMed
  61. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008 Dec; 15(4):1069-74. Epub 2008 Aug 21
    View PubMed
  62. Ricarte-Filho JCM, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers by mass spectrometry reveals distinct roles for BRAF, PIK3CA and AKT1 in disease pathogenesis. Cancer Research. 2008; 69:4885-93.
  63. Ryder M, Nikiforov YE, Fagin JA. Follicular variant papillary thyroid carcinoma arising within an ovarian teratoma. Thyroid. 2007 Feb; 17(2):179-80.
    View PubMed
  64. D'Souza, MM, Carr, J. A Characterization of [125I]beta-endorphin binding sites in the rat caudal dorsomedial medulla. Peptides.1998;19:931-937.
  65. Carr, JA, D'Souza, MM, Elmore, AR, Lovering, AT, Reigel, CE. Alterations in brain and pituitary beta-endorphin content in genetically epilepsy-prone rats. Epilepsy Res.1998;31:113-122.
PST-20227496